市場調查報告書

全球動物用抗感染藥市場:成長,趨勢,及預測

Veterinary Anti-infectives Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 925207
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
全球動物用抗感染藥市場:成長,趨勢,及預測 Veterinary Anti-infectives Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

本報告提供全球動物用抗感染藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,動物類型·產品類型·給藥途徑·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 人獸通用感染疾病及食源性疾病的增加
    • 寵物擁有率的上升
    • 動物醫療保健研究開發活動的增加
  • 市場阻礙因素
    • 偽造醫藥品的使用
    • 獸醫服務成本的增加
  • 波特的五力分析

第5章 市場區隔

  • 各動物類型
    • 家禽
    • 其他
  • 各產品類型
    • 抗菌
    • 抗病毒藥物
    • 抗真菌劑
    • 其他
  • 各給藥途徑
    • 口服
    • 局部
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale
    • Elanco
    • Merck & Co Inc.
    • Phibro Animal Health Corporation
    • Vetoquinol SA
    • Virbac
    • Zoetis Inc.

第7章 市場機會及今後趨勢

目錄
Product Code: 50008

The prevention and treatment of deadly animal diseases are key market indicators for veterinary anti-infectives. Certain factors such as increasing zoonotic and foodborne diseases, rising pet ownership and rising R&D activities in animal healthcare. The zoonotic and foodborne diseases are naturally transmitted from animals to humans, due to the consumption of contaminated food and water, exposure to the pathogen during preparation, processing, or by direct contact with infected animals or humans. Zoonotic diseases are quite common around the world. According to the scientists of Centers for Disease Control and Prevention (CDC), over 6 out of every 10 known infectious diseases in humans are spread via animals, moreover, 3 out of every 4 new or emerging infectious diseases are spread from animals. So, it is evident that these diseases are major public health problem worldwide. Thus, increasing burden of zoonotic diseases is expected to impact the growth of the market.

Key Market Trends

Cattle Sub-Segment is Expected to Show Better Growth in the Forecast Years

Based on Animal Type, it is segmented into cattle, poultry, cats, dogs and other animals. The growth of the cattle sub-segment is mainly attributed to the high population of cattle across the world and the dominance of cattle farming as a major income source for people in many countries. For example, in countries such as China and Mexico where the livestock population is high, the market for cattle anti-infective products is larger compared to the developed countries. According to the Food and Agriculture Organization (FAO), the worldwide population of cattle is more than 1.4 billion, out of which a large proportion is noted in countries such as India, Brazil, and China. Furthermore, in 2019, Bimeda received FDA approval for OxyMed LA indicated to treat bacterial enteritis in swine and cattle. Hence, new product approval, awareness about cattle diseases and zoonosis are anticipated to have a positive impact on the market in the coming years.

North America Dominates the Veterinary Anti-infectives Market

North America region is among the major contributor to livestock and the implementation of animal healthcare benefits across the region. The market is growing rapidly due to the presence of advanced animal healthcare programs coupled with awareness regarding animal health is projected to drive the regional market growth. According to 2017 data by the North American Meat Institute, the poultry and meat industries are the largest division of the United States agriculture sector. Moreover, rising disease burden in animals is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the veterinary anti-infectives market are - Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale, Elanco, Merck & Co Inc., Phibro Animal Health Corporation, Vetoquinol S.A., Virbac and Zoetis Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Zoonotic and Foodborne Diseases
    • 4.2.2 Rising Pet Ownership
    • 4.2.3 Rising R&D Activities in Animal Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Use of Counterfeit Medicines
    • 4.3.2 Increasing Cost of Veterinary Services
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Animal Type
    • 5.1.1 Cattle
    • 5.1.2 Poultry
    • 5.1.3 Cats
    • 5.1.4 Dogs
    • 5.1.5 Other Animals
  • 5.2 By Product Type
    • 5.2.1 Antibacterial
    • 5.2.2 Antivirals
    • 5.2.3 Antifungals
    • 5.2.4 Others
  • 5.3 By Mode of Administration
    • 5.3.1 Oral
    • 5.3.2 Topical
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 France
      • 5.4.2.2 Germany
      • 5.4.2.3 United Kingdom
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Boehringer Ingelheim GmbH
    • 6.1.3 Ceva Sante Animale
    • 6.1.4 Elanco
    • 6.1.5 Merck & Co Inc.
    • 6.1.6 Phibro Animal Health Corporation
    • 6.1.7 Vetoquinol S.A.
    • 6.1.8 Virbac
    • 6.1.9 Zoetis Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS